ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
ELAVL1 Stabilizes HMOX1 mRNA to Drive Ferroptosis in Diabetic Retinopathy.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis in retinal neurodegeneration: mechanistic vulnerability, therapeutic targeting, and translational barriers.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the role of heme oxygenase 1 (HMOX1) in the pathogenesis of diabetic retinopathy (DR) and identify the RNA-binding protein embryonic lethal abnormal vision-like 1 (ELAVL1) as a novel regulator of HMOX1 mRNA stability driving ferroptosis, proposing ELAVL1 as a potential therapeutic target for DR. Methods: DR was modeled in vitro using high glucose (HG)-treated ARPE19 cells and in vivo via streptozotocin (STZ)-induced diabetic rats. Cell damage was assessed through measuring cell viability, oxidative stress markers, iron content, and ferroptosis-related protein expression. HMOX1 expression and its regulatory interaction with ELAVL1 were analyzed using RT-qPCR, immunohistochemistry, Western blotting, RNA-fluorescence in situ hybridization, and RNA immunoprecipitation. Functional roles were validated by gene knockdown or overexpression experiments. Results: HG stimulation induced ferroptosis-related damage and oxidative stress in ARPE19 cells and the retinas of DR rats, accompanied by a significant upregulation of HMOX1 expression (approximately 165% in vivo and 189% in vitro). Knockdown of either HMOX1 or ELAVL1 effectively suppressed ferroptosis and mitigated retinal degeneration. Conclusion: HMOX1 is critical for ferroptosis-mediated retinal damage in DR, and ELAVL1 promotes ferroptosis predominantly by stabilizing HMOX1 mRNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.